The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -90,597 |
| Depreciation and amortization | 8,436 |
| Amortization (accretion) of premium (discount) on marketable securities | 411 |
| Stock-based compensation | 13,046 |
| Non-cash operating lease expense | 2,473 |
| Other | -423 |
| Prepaid expenses and other current assets | -547 |
| Other noncurrent assets | -571 |
| Accounts payable | -1,430 |
| Accrued and other current liabilities | 532 |
| Operating lease liabilities | -2,778 |
| Other noncurrent liabilities | 102 |
| Net cash used in operating activities | -68,264 |
| Purchases of property and equipment | 618 |
| Purchases of marketable securities | 0 |
| Proceeds from sales of marketable securities | 10,958 |
| Proceeds from maturities of marketable securities | 45,743 |
| Other | 0 |
| Net cash provided by investing activities | 56,083 |
| Proceeds from issuance of equity, net of issuance costs-Follow On Offering | 105,065 |
| Proceeds from exercise of stock options and employee stock purchase plan | 139 |
| Proceeds from exercise of warrants | 2,289 |
| Proceeds from exercises of pre-funded warrants | 0 |
| Proceeds from issuance of equity, net of issuance costs-At The Market Offering | 912 |
| Net cash provided by financing activities | 108,405 |
| Net change in cash, cash equivalents and restricted cash | 96,224 |
| Cash and cash equivalents and restricted cash at beginning of period | 4,742 |
| Cash and cash equivalents and restricted cash at end of period | 100,966 |
Tenaya Therapeutics, Inc. (TNYA)
Tenaya Therapeutics, Inc. (TNYA)